Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.11
+$0.02 · +0.96%
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Previous close
$2.11
+$0.02 · +0.96%
Regular session · ET · Market data may be delayed.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Day range
Current $2.11
52-week range
Current $2.11
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
68
Undervalued
Sentiment
33
Bearish
Risk
62
High Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Day range
Current $2.11
52-week range
Current $2.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 109.16M USD | 6.59M USD | 2.24M USD | 5.2M USD | — |
| Cost of goods sold | 13.1M USD | — | — | — | 4.58M USD |
| Gross profit | 96.06M USD | 6.59M USD | 2.24M USD | 5.2M USD | −4.58M USD |
| Research and development | 95.67M USD | 107.24M USD | 92.71M USD | 97.17M USD | 75.65M USD |
| Selling, general, and administrative | 24M USD | 33.16M USD | 34.71M USD | 31.86M USD | 14.65M USD |
| Operating expenses | 111.1M USD | 144.73M USD | 148.78M USD | 139.03M USD | 90.3M USD |
| Interest income | 7.35M USD | 13.01M USD | 12.68M USD | 2.99M USD | 898K USD |
| Interest expense | — | — | 540K USD | — | 1.28M USD |
| Depreciation and amortization | 13.1M USD | 13.3M USD | 13.04M USD | 8.44M USD | 4.58M USD |
| Operating income | −15.04M USD | −138.14M USD | −146.55M USD | −133.83M USD | −94.88M USD |
| Net income | −9.58M USD | −126.57M USD | −136.67M USD | −130.93M USD | −95.82M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
5.21% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.77M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM6.22M0.01%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF2.47M0.00%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN2.29M0.02%14.61B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO1.39M0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC877.55K0.06%1.49B USD0.60%$196.25+0.69%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS468.66K0.17%282.64M USD0.39%$52.595-0.03%
Avantis U.S. Small Cap Equity ETFAVSC458.34K0.01%3.15B USD0.25%$73.23+0.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco Russell 2000 Dynamic Multifactor ETFOMFSAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
